# Verrica Pharmaceuticals (VRCA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VRCA
## Company Profile
- Ticker: VRCA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.31 USD
- Market cap: 99465170.94 USD
- Last updated: 2026-10-05
## Business Overview
### Medical Dermatology
Verrica Pharmaceuticals develops and commercializes treatments for dermatologic diseases, including viral skin conditions and non-melanoma skin cancers.
### YCANTH for Molluscum
YCANTH is a drug-device combination containing a controlled formulation of cantharidin in a single-use applicator. It is the first FDA-approved, healthcare-professional-administered treatment for molluscum contagiosum in adults and children two years of age and older.
### Common-Wart Expansion
Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts. The program is intended to extend the product into a substantially larger dermatology population.
### VP-315 Skin-Cancer Program
VP-315, or ruxotemitide, is a licensed oncolytic peptide being prepared for Phase 3 development in basal cell carcinoma. The broader license also covers other non-melanoma skin cancers, including squamous cell carcinoma.
## Why The Stock Is Moving

As of Oct 5, 2026, VRCA closed down 1.60% at $4.31. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from the global Phase 3 YCANTH program in common warts in mid-2027.

## Drug Assets

- VP-315

## Recent News
- 2026-09-30 12:01 EST — [Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-present-new-ycanth-data-analysis-at-two-upcoming-derm-73034727) — Source: Verrica Pharmaceuticals
- 2026-09-10 12:05 EST — [Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-present-ycanth-and-vp-315-data-at-two-upcoming-dermat-f16d2442) — Source: Verrica Pharmaceuticals
- 2026-09-08 12:05 EST — [Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-28th-annual-global--9530384d) — Source: Verrica Pharmaceuticals
- 2026-08-27 12:00 EST — [Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-completion-of-enrollment-in-first-pivotal-phas-16e68622) — Source: Verrica Pharmaceuticals
- 2026-08-06 20:05 EST — [Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2026-financial-results-10f4a960) — Source: Verrica Pharmaceuticals